Recent News

• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
• 06.05.2025 - KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
• 06.03.2025 - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.03.2025 - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.02.2025 - KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
• 06.02.2025 - KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
• 05.29.2025 - KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
• 05.29.2025 - KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
• 05.22.2025 - KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings

Recent Filings

• 05.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors